Management of chronic myeloid leukaemia.
Goldman
J M
JM
LRF Centre for Adult Leukaemia, Royal Postgraduate Medical School, London, UK.
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D001752:Blast Crisis / Q000188:drug therapy / Q000601:surgery; D016026:Bone Marrow Transplantation / Q000706:statistics & numerical data; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy; D016016:Proportional Hazards Models; D012074:Remission Induction; D016019:Survival Analysis
D007155:Immunologic Factors; D016898:Interferon-alpha; D002066:Busulfan; D006918:Hydroxyurea